Quick Answer
Oruka Therapeutics, Inc. reported Net Income of -$105.43 million for fiscal year 2025.
Oruka Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$105.43M | -25.9% |
| 2024 | -$83.72M | -1468.2% |
| 2023 | -$5.34M | +46.2% |
| 2022 | -$9.93M | +48.6% |
| 2021 | -$19.32M | -98.4% |
| 2020 | -$9.74M | -77.6% |
| 2019 | -$5.48M | +30.9% |
| 2018 | -$7.93M | +57.1% |
| 2017 | -$18.49M | -12.4% |
| 2016 | -$16.44M | -43.7% |
| 2015 | -$11.45M | -18.1% |
| 2014 | -$9.69M | -39.6% |
| 2013 | -$6.94M | -60.6% |
| 2012 | -$4.32M | +19.5% |
| 2011 | -$5.36M | +36.3% |
| 2010 | -$8.42M | +7.9% |
| 2009 | -$9.14M | +53.0% |
| 2008 | -$19.43M | -38.9% |
| 2007 | -$13.99M | -167.0% |
| 2006 | -$5.24M | -259.2% |
| 2005 | -$1.46M | -185.5% |
| 2004 | -$511.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.28M | -5.8% | -23.2% |
| June 30, 2025 | -$24.57M | -10.5% | -17.0% |
| March 31, 2025 | -$21.00M | -196.7% | +26.6% |
| September 30, 2024 | -$28.62M | -1910.0% | -28.7% |
| June 30, 2024 | -$22.24M | -1402.9% | -214.3% |
| March 31, 2024 | -$7.08M | -425.8% | -549.9% |
| December 31, 2023 | -$1.09M | +7.2% | +23.5% |
| September 30, 2023 | -$1.42M | +39.0% | +3.8% |
- Oruka Therapeutics, Inc. showed a decrease of -25.9% in Net Income compared to the prior fiscal year.
- Over the 2004–2025 period, Oruka Therapeutics, Inc.’s net income has declined by 20532.7% (from -$511.0 thousand to -$105.43 million).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: